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Cyclic alternating patternPeriodic limb movement disorder (PLMD) is characterized by pathological periodic limb movements during
sleep, insomnia and/or diurnal sleepiness, and the absence of another primary sleep disorder.We report a patient
with complex partial seizures who developed PLMD while taking topiramate (TPM). He had no evidence of
metabolic and/or other conditions inducing PLMD. He also had fragmented sleep and disruptive PLMS on
polysomnography, and PLMS subsidedwith change of antiepileptic drug. Topiramatemaymodulate the dopami-
nergic pathway by inhibition of glutamate release, thereby inducing PLMD as observed in our patient. Although a
single case does not allow any generalization, PLMD should be considered in patients complaining of insomnia
and treated with TPM.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Periodic limb movement disorder (PLMD) is diagnosed when there
are periodic limb movements during sleep (PLMS) exceeding norms
for age, clinical sleep disturbance, and the absence of another primary
sleep disorder or reason for the PLMS [1]. Pathological periodic limb
movement index (PLMI) is deﬁned as N15 movements/h in adults [1].
Periodic limb movement disorder is rarer than restless legs syndrome
(RLS), which is characterized by the sensorymotor symptoms frequent-
ly associated with PLMS, usually occurring at night and leading to
disrupted sleep and daytime fatigue as in neuromuscular disorders [2].
Several medications are known to induce and/or to worsen PLMD (i.e.,
antidepressants, antihistamines, and antipsychotics) [3]. Although alter-
native RLS/PLMD treatments include antiepileptic drugs (AEDs) [4], in
contrast, topiramate (TPM)-induced RLS also associated with PLMS was
described in four patients affected by epilepsy [5,6]. We report a case of
TPM-induced PLMD in a patient affected by cryptogenic temporal lobe
epilepsy lacking a history of previous sleep disorders.
2. Case report
A 34-year-old male affected by cryptogenic temporal lobe epilepsy
previously treated with carbamazepine (up to 1200 mg per day)CS Neuromed, Via Atinense 18,
55221.
. This is an open access article undermanifested monthly complex partial seizures. Topiramate slowly titrat-
ed up to 250mg per day induced seizure freedom and, afterward, carba-
mazepine was discontinued. Concurrently, he complained of insomnia,
nonrestorative sleep, and daytime sleepiness (Epworth Sleepiness
Scale (ESS) score: 16). In addition, his wife reported the appearance of
frequent nocturnal legmovements thatwere never previously observed.
The patient also denied having had prior similar symptoms. Serum ex-
amination (blood count, electrolytes, liver and renal function, thyroid
hormones, and iron and ferritin levels) was unremarkable. Therefore,
our patient underwent a full polysomnography (PSG) that showed a se-
vere PLMD (PLMI: 62.7/h) associated with high PLM arousal index
(PLMAI: 11.9/h); low sleep efﬁciency; high sleep latency, wakefulness
after sleep onset, and number of awakenings; high percentage of light
sleep (N2); and low percentage of slow-wave sleep (N3) (see Table 1).
Periodic limb movements during sleep were strictly associated
with periodic electroencephalographic arousals and cyclic alternat-
ing pattern (CAP). In particular, CAP oscillations were triggered by
PLM with higher presence of CAP subtypes A2 and A3 (see Fig. 1).
These CAP subtypes represent an arousal phenomenon that likely
leads to clinical correlates of disturbed sleep. Respiratory distur-
bance index and oxygen desaturation index were normal. Therefore,
because of the progressive impairment of insomnia and daytime dys-
function, TPMwas slowly discontinued and switched to valproate up
to 900 mg per day. During TPM discontinuation and after complete
withdrawal, the patient underwent full PSG (TPM: 50 mg per day).
Periodic limb movement index and periodic limb movement arousal
index showed a signiﬁcant improvement and, after TPM discontinu-
ation, reached a normal value (PLMI b 15/h). Polysomnographythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1






TST, total sleep time (min) 399 510 495
Sleep efﬁciency (%) 81.5% 93.1% 97.2%
Sleep latency (min) 22 12 13
n awakenings 29 (4.4/h) 17 (2/h) 4 (0.1/h)
n REM periods 3 4 5
REM latency (min) 80.5 92 80
WASO (min) 68 43 14.1
% N1 2.3 6.2 0.4
% N2 62.8 32 49.7
% N3 21.5 42.2 23.3
% REM 13.5 19.5 16.6
RDI 0.7/h 1.7/h 1.2/h
CAP rate (%) 66.3 47.7 45.1
A1 (%) 23.7 33.4 42.5
A2 (%) 41.8 44.5 27.7
A3 (%) 34.5 22.1 29.8
ODI 0.8/h 1.4/h 0.7/h
PLMI 62.7/h 21.5/h 11.6/h
PLMAI 11.9/h 3.4/h 0.9/h
PLMW 50.2/h 5.2/h 6.7/h
ESS score 16 11 10
RDI, respiratory disturbance index; ODI, oxygen desaturation index; PLMI, periodic limb
movement index; PLMAI, periodic limb movement arousal index; PLMW, periodic limb
movements during wakefulness; CAP, cyclic alternating pattern; A1, CAP phase A1; A2,
CAP phase A2; A3, CAP phase A3; ESS score, Epworth Sleepiness Scale score.
Fig. 1. Two-minute segment of full polysomnography (TPM: 250 mg per day) showing periodic
(RTib and LTib) and of the chin (EMG) occur after the onset of theA phase (A2 and A3) of the cyc
the progressive reduction of PLMS and CAP rate, particularly phases A2 and A3, considered a m
122 A. Romigi et al. / Epilepsy & Behavior Case Reports 2 (2014) 121–123variables and ESS scores showed remarkable amelioration (see
Table 1). In addition, the CAP rate exhibited a slight reduction, an in-
crease of CAP phase A1 and a parallel reduction of phases A2 and A3.
All PSG data are summarized in Table 1. In order to evaluate the asso-
ciation between TPM and PLMD, the Naranjo probability scale [7]
documented a probable association (Naranjo score: 8/13) between
PLMD and TPM intake.
3. Discussion
This is the ﬁrst publication, to our knowledge, to describe TPM-
induced PLMD in a patient affected by cryptogenic temporal lobe epi-
lepsy previously not complaining of sleep disorders. Although there is
a high night-to-night variability of PLMI in PLMD/RLS that may inﬂu-
ence our results, this issue is still controversial, and the nocturnal pat-
tern of PLM occurrence was highly reliable across nights, suggesting
that a single-night study may be sufﬁciently sensitive to conﬁrm diag-
nosis and associated sleep disturbances [8]. Therefore, we can state
that PLMD was probably induced by TPM in our patient.
In addition, RLS and PLMD pathophysiology is highly debated; a
common central dysregulation of dopaminergic system seems to be
implicated [9]. This hypothesis is supported by the efﬁcacy of dopami-
nergic treatment for both sleep disorders. Several drugs with a dopa-
mine-modulating proﬁle may provoke RLS and/or PLMD [3]. Although
such AEDs may be effective treatments for RLS and PLMD, TPM-inducedlimbmovement during NREM sleep (N2). The muscle contractions of the anterior tibialis
lic alternating pattern and follow the same cyclic recurrence. The TPMwithdrawal induced
arker of sleep instability.
123A. Romigi et al. / Epilepsy & Behavior Case Reports 2 (2014) 121–123RLSwas previously described in a few cases [5,6]. Topiramate showsmul-
tiple mechanisms of action. Topiramate enhances GABA function and
inhibits AMPA and kainate glutamate pathways, inducing an extra-
cellular modulation of dopamine release in the mesocorticolimbic
dopamine system [10]. These experimental lines of evidence are
conﬁrmed by its efﬁcacy against alcohol, nicotine, and cocaine addic-
tions [11,12]. Therefore, we can hypothesize that TPMmaymodulate
the dopaminergic pathway, thereby inducing PLMD in subjects with
speciﬁc individual susceptibility.
On the other hand, the clinical signiﬁcance of PLMS lacking RLS
symptoms is still debated. Patients showing PLMS may complain of in-
somnia and daytime dysfunction. High levels of EEG arousals and/or
CAP sequences prior to leg movements conﬁrm the presence of sleep
impairment in these patients [13,14]. Periodic limb movements are
short movements that can be entrained by central pattern genera-
tors in reciprocal oscillatory coupling. Speciﬁcally, CAP phases A2
and A3 that represent arousal phenomena are more probably associ-
ated with disturbed sleep [14] as also demonstrated polygraphically
in our patient (Fig. 1). The patients are typically not aware of
these limb movements, but quality of sleep may be compromised,
and the bed partners might recognize PLMS. Even though the litera-
ture failed to document a clear correlation between PLMS severity
and sleep disruption [13], Haba-Rubio et al. [15] found a correlation
between PLMS and tiredness, sleep efﬁciency, and psychological
well-being.
Periodic limb movement disorder, insomnia, and diurnal symptoms
promptly recovered after drug discontinuation in our patient suggesting
a probable association with TPM.We are aware that, regarding themu-
tual interactions between sleep and epilepsy, not only sleep deprivation
and daytime sleepiness but also abnormal sleep per se represent well-
known potential triggers for seizures and are themselves inﬂuenced
by epilepsy in a sort of reciprocal effect. Notwithstanding, comorbidities
and pharmacological treatment are other commonly accepted major
factors that inﬂuence this interplay. Therefore, an accurate clinical histo-
ry and PSG study in selected cases could be useful in order to recognize
potential drug-induced sleep disorders.Conﬂict of interests
On behalf of all authors, the corresponding author states that there is
no conﬂict of interest.
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